Penningtons Manches Cooper LLP has a strong track record in international M&A and venture capital transactions and offers ‘very practical and helpful advice‘ to major clients in the life sciences, technology and renewable energy sectors, according to The Legal 500.
The firm is placed in Tier 1 in corporate & commercial in the Thames Valley – alongside Blake Morgan, Osborne Clarke and Shoosmiths.
Oxford-based partners Will Axtell and James Went specialise in M&A, fundraisings and AIM capital markets. In Reading Rob Hayes acts on behalf of investors and investee companies in mid-market M&A and venture capital transactions.
Practice head(s): Will Axtell
Other key lawyers:James Went; Rob Hayes
‘Pennington Manches team possess an excellent combination of technical expertise and commercial understanding‘
‘The team at Penningtons Manches combined undoubted legal expertise with emotional intelligence‘.
‘Will Axtell is a quick thinker who took the time to understand the business and the deal. He is a truly fantastic lawyer with tremendous skills and experience in the business‘.
Business Growth Fund
Oxford University Press
Ethical Property Company
Touchstone Innovations Plc
- Assisted Enterprise Therapeutics on the closing of a circa £29m series B funding round.
- Advised MedPharm on a growth equity investment from private equity firm Ampersand Capital Partners.
- Acted on behalf of the majority shareholder on the disposal of their interests to FTSE-100 listed utilities company, Severn Trent Plc, in a transactions totalling £120m.
- Represented Oxford Vacmedix on its Series A financing round of approximately £9m with a consortium of South Korean and Chinese investors.